The role of JAK inhibitors in multiple myeloma.

The role of JAK inhibitors in multiple myeloma. Clin Adv Hematol Oncol. 2019 Sep;17(9):500-505 Authors: Ghermezi M, Spektor TM, Berenson JR Abstract Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of MM. Many newer drugs have been evaluated together and in combination with older agents. However, even in combination with other active MM agents, the responses are transient, and; thus, therapeutic approaches to help overcome resistance to these drugs are necessary. Recently, the Janus kinase (JAK) family of tyrosine kinases, including JAK1 and JAK2, has been shown to play a role in the pathogenesis of MM. Preclinical studies have demonstrated that the JAK1/2 inhibitor ruxolitinib, in combination with lenalidomide and dexamethasone, reduces proliferation of the MM cell lines and primary tumor cells derived from MM patients, and this inhibition is greater when these drugs are combined than with single agents. Clinically, early results from the oral treatment regimen of ruxolitinib, corticosteroids (methylprednisolone), and lenalidomide for patients with relapsed/refractory disease are encouraging in terms of safety and efficacy, and additional studies will provide further support for this promising new therapeutic approach for patients with MM. PMID: 31...
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Related Links:

The diagnosis of primary systemic amyloidosis, also known as AL (amyloid light-chain) amyloidosis, is often delayed owing to its nonspecific manifestations as well as its rarity. A 64-year-old woman presented with an eight-month history of significant weight loss, anemia, fatigue, and progressive painful cutaneous lesions on her hands, lips, back, perianal, and vulvar area that were originally treated unsuccessfully with antimalarials and systemic corticosteroids. Histopathological examination revealed an amorphous dermis with pale pink material that demonstrated positive birefringence with Congo red staining. Subsequently...
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
Pomalidomide (pom), an immunomodulatory agent, in combination with low-dose dexamethasone (dex), is approved for the treatment of multiple myeloma (MM) refractory to lenalidomide (R) and bortezomib (V). Herein we report on the efficacy and safety of pom with/without dex in the real world setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Corticosteroids (steroids) play a central role in the treatment of MM and are widely recognised to cause a wide range of side effects that adversely impact health related quality of life (HRQoL). Patient reported outcome measures (PROMs) are tools that enable patients to report their health status and the presence and severity of symptoms. A range of PROMs are available to assess symptoms in MM but no such tool exists to measure the impact of steroids in this population. The Dexamethasone Symptom Questionnaire Chronic (DSQ-C) is an 18-item measure, initially developed to determine the incidence and severity of symptoms exp...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Corticosteroids remain the backbone of treatment for myeloma, recognised to cause a wide range of side effects. To date, as no instrument exists, the frequency and severity of these side effects are not reported as part of the routine care. The Dexamethasone Symptom Questionnaire Chronic (DSQ-Chronic) was designed to report side effects associated to dexamethasone given as an anti-emetic in cancer patients. We adapted the DSQ-C to reflect the higher doses and duration of treatment in a Multiple Myeloma (MM) population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
POEMS syndrome is a rare paraneoplastic syndrome caused by an underlying plasma cell disorder. The combination of a proteasome inhibitor, an IMiD and corticosteroid is known to be highly effective among patients with myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
The FDA granted accelerated approval to the nuclear transport inhibitor selinexor in combination with the corticosteroid dexamethasone for patients with relapsed or refractory multiple myeloma. Marketed as Xpovio, the drug is indicated for patients treated with at least 4 prior therapies whose disease has developed resistance to other treatments, including at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Source: JAMA - Category: General Medicine Source Type: research
SOCOS group Abstract The International Staging System (ISS) -calculated from serum albumin and beta-2 microglobulin (β2m)- is an established prognostic marker in multiple myeloma (MM), which has also been suggested to account for survival among general senior population. Our objective was to examine long-term survival of older women free of MM according to baseline ISS. The study included 230 community-dwelling healthy older women without known MM from the EPIDOS cohort (mean ± SD, 80.4 ± 3.4 years). Serum albumin and β2m were measured at baseline, and used to calculate the ISS a ...
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Eur J Intern Med Source Type: research
(H. Lee Moffitt Cancer Center&Research Institute) A first-in-class drug recently granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with heavily pretreated multiple myeloma has been the subject of study at Moffitt Cancer Center for years. Now, selinexor (XPOVIO ™ , Karyopharm Therapeutics) used in combination with the corticosteroid dexamethasone will offer another option for patients with multiple myeloma who have exhausted the most common therapies for the disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
We report a case of Nocardia farcinica ruptured intracranial mycotic aneurysm associated with bortezomib and corticosteroid treatment in a multiple myeloma patient. The patient was treated with trimethoprim-sulfamethoxazole and moxifloxacin together with surgical repairment of intracranial mycotic aneurysm.
Source: IDCases - Category: Infectious Diseases Source Type: research
XPOVIO is a drug used to treat a form of blood cancer called multiple myeloma. It is to be used in combination with dexamethasone (a type of corticosteroid) in patients with no other treatment options whose cancer came back after, or did not respond to, at least four previous treatments.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
More News: Cancer & Oncology | Corticosteroid Therapy | Dexamethasone | Hematology | Methylprednisolone | Myeloma | Revlimid | Study